Immune cell therapy for advanced hepatitis B-related liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new immune cell therapy (LioCyx-M) for people with advanced liver cancer caused by hepatitis B. It uses specially designed T cells (a type of immune cell) that target the hepatitis B virus and may help fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (HCC).
- Your cancer cannot be removed by surgery or local treatments, or has gotten worse despite those treatments.
- You have already tried at least one systemic cancer medicine (like a pill or infusion) that hasn't worked.
- You are generally active and able to take care of yourself (ECOG score 0 or 1).
- You test positive for hepatitis B surface antigen (HBsAg).
- You have well-preserved liver function (Child-Pugh score A, meaning your liver is working fairly well).
- Your immune system has a specific genetic type (HLA-A*02:01 or HLA-A*24:02), which will be checked with a blood test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
This study tests a new immune cell therapy (SCG101) for people with a certain type of liver cancer linked to hepatitis B. It's designed for those whose cancer has progressed after standard treatments.
This trial tests lab-made immune T cells that target hepatitis B (HBV) using a treatment called LioCyx-M, either alone or with lenvatinib. It’s for people with advanced HBV-related hepatocellular carcinoma (liver cancer) who can’t be cured with surgery or local procedures.
This Phase 1 study tests a lab-made immune cell treatment that targets hepatitis B (HBV)–related liver cancer. It may help by directing the body’s immune system to attack the cancer, while carefully checking safety.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.